핵산 검사 시장 : 제품 유형, 기술, 검체 유형, 표적 분자, 자동화 정도, 임상 목적, 용도, 최종사용자별 - 시장 예측(2026-2032년)

The Nucleic Acid Testing Market is projected to grow by USD 19.77 billion at a CAGR of 9.50% by 2032.

Nucleic acid testing, or NAT, is the molecular diagnostics category that detects DNA or RNA from pathogens, inherited conditions, oncology biomarkers, donor blood samples, and other clinically relevant targets. The field includes polymerase chain reaction, reverse transcription PCR, transcription-mediated amplification, loop-mediated isothermal amplification, next-generation sequencing, and digital PCR. Its value proposition is speed, analytical sensitivity, specificity, and the ability to detect infection before serology becomes positive.

Demand remains structurally supported by infectious disease surveillance, blood screening, transplant safety, oncology companion diagnostics, reproductive health, antimicrobial resistance monitoring, and decentralized testing. Public health agencies including WHO, CDC, FDA, ECDC, Africa CDC, and national reference laboratories continue to position molecular testing as a core tool for outbreak detection, treatment decisions, and population-level disease control.

Transformative Shifts in the NAT Landscape

The nucleic acid testing landscape is shifting from centralized, high-complexity laboratories toward a hybrid model that combines reference-lab scale with point-of-care and near-patient access. COVID-19 accelerated installed instrument bases, sample-to-answer workflows, multiplex respiratory panels, laboratory automation, and buyer expectations for faster turnaround times and supply-chain resilience.

A second shift is the move from single-analyte assays to syndromic, quantitative, and sequencing-enabled diagnostics. Hospitals and public health laboratories increasingly require tests that distinguish pathogens with overlapping symptoms, quantify viral load, and identify resistance markers. Regulatory scrutiny is also increasing, particularly for laboratory-developed tests and decentralized platforms, making analytical validation, clinical evidence, cybersecurity, and quality management central competitive differentiators.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence nucleic acid testing across assay design, laboratory operations, result interpretation, and epidemiologic intelligence. Machine learning can accelerate primer and probe selection, evaluate sequence conservation, flag emerging variants, and reduce the risk of assay dropout when pathogens mutate. In sequencing workflows, AI-supported bioinformatics improves variant calling, contamination detection, and clinically relevant classification.

The cumulative impact is operational as well as clinical. AI-enabled demand planning can help laboratories manage reagents and staffing, while automated signal interpretation can support digital PCR and high-throughput platforms. Industry leaders should treat AI as a validated decision-support layer, not a substitute for quality systems, clinical governance, and regulatory-grade evidence.

Key Regional Insights: Asia-Pacific, North America, Europe, and Emerging Regions

Asia-Pacific is a high-priority region for nucleic acid testing because of large patient populations, expanding hospital networks, tuberculosis burden, hepatitis screening, and government investment in domestic diagnostics. China, India, Japan, South Korea, and Australia anchor demand through public health programs, oncology testing, reproductive health, blood safety, and growing use of sequencing in clinical and academic settings.

North America remains the most mature commercialization environment, led by the United States and Canada, where FDA oversight, CLIA laboratories, broad hospital adoption, and reimbursement pathways shape innovation. Europe benefits from strong public health infrastructure, ECDC coordination, IVDR implementation, and established molecular diagnostics adoption across Germany, France, Italy, Spain, and the United Kingdom.

Latin America is expanding NAT access through infectious disease testing, blood safety, and private laboratory networks, with Brazil and Mexico serving as major demand centers. The Middle East is investing in precision medicine, transplant safety, and hospital modernization, especially in GCC markets. Africa is advancing molecular capacity through HIV viral load, tuberculosis, Ebola, mpox, and malaria surveillance, supported by Africa CDC, WHO programs, and donor-backed laboratory networks.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN demand is supported by dengue, tuberculosis, hepatitis, HIV, influenza, and hospital-acquired infection surveillance, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines investing in laboratory modernization at different speeds. The GCC is characterized by high healthcare spending, imported technology adoption, and national genomics and precision medicine programs that create opportunities for automated NAT systems.

The European Union is defined by harmonized regulatory transition under the In Vitro Diagnostic Regulation, cross-border disease surveillance, and strong reference-laboratory capacity. BRICS economies combine scale with local manufacturing ambitions; China and India are particularly important for cost-optimized platforms and high-volume infectious disease testing. G7 markets influence global standards through regulatory science, reimbursement policy, and innovation funding, while NATO countries increasingly view molecular diagnostics as part of biosecurity, preparedness, and resilient medical supply chains.

Key Country Insights Across Major NAT Markets

The United States leads NAT innovation through FDA-cleared and authorized assays, CLIA-certified laboratory networks, hospital molecular testing, and strong biomedical funding. Canada emphasizes public healthcare procurement, respiratory virus surveillance, and oncology diagnostics, while Mexico and Brazil are expanding molecular capacity through public-private laboratory networks, blood safety, and infectious disease programs.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine advanced clinical laboratories with national health systems that prioritize evidence, cost-effectiveness, and regulatory compliance. Russia maintains domestic testing capacity for infectious disease and public health use. China is scaling local molecular platforms, oncology genomics, and infectious disease surveillance; India is expanding affordability-focused molecular access for tuberculosis, viral hepatitis, and reproductive health. Japan, South Korea, and Australia are mature, quality-driven markets with strong demand for automated, multiplex, and sequencing-based NAT solutions.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize assays and platforms that address high-burden clinical needs, deliver measurable workflow efficiency, and comply with evolving regulatory expectations. The most defensible strategies combine validated clinical performance, scalable manufacturing, stable reagent supply, cybersecurity, interoperability with laboratory information systems, and clear health-economic evidence.

Organizations should also localize market access strategies. In mature markets, differentiation depends on automation, multiplexing, turnaround time, reimbursement support, and evidence generation. In emerging markets, success requires affordability, service uptime, training, sample logistics, and partnerships with public health agencies. AI, sequencing, and point-of-care NAT should be adopted with rigorous validation, transparent performance metrics, and post-market monitoring.

Research Methodology

This executive summary is built from a secondary research methodology using publicly available, authoritative sources and cross-validated industry indicators. Core reference points include WHO disease surveillance, CDC testing guidance, FDA diagnostics policy, ECDC public health reporting, IVDR regulatory information, Africa CDC priorities, national health agencies, peer-reviewed literature, and established laboratory medicine standards.

The analysis prioritizes verified trends over speculative estimates. Insights were synthesized across clinical use cases, technology platforms, regional healthcare infrastructure, regulatory frameworks, procurement behavior, and public health demand drivers. Market interpretation focuses on structural forces affecting nucleic acid testing adoption rather than unverified revenue projections.

Conclusion

Nucleic acid testing has moved from a specialized molecular tool to a foundational component of modern healthcare, public health preparedness, blood safety, oncology, and precision medicine. Its continued relevance is supported by the need for earlier detection, faster therapeutic decisions, antimicrobial resistance monitoring, and real-time surveillance of emerging pathogens.

The next phase of competition will be shaped by automation, multiplex panels, sequencing integration, AI-supported analytics, and decentralized access. Organizations that combine analytical accuracy with operational reliability, regulatory discipline, and market-specific affordability will be well positioned to advance in the global NAT ecosystem.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Nucleic Acid Testing Market, by Product Type

• 7.1. Instruments
• 7.2. Reagents & Kits
• 7.3. Software & Services

8. Nucleic Acid Testing Market, by Technology

• 8.1. Digital PCR
• 8.2. Isothermal Amplification
• 8.3. Microarray
• 8.4. Next Generation Sequencing
• 8.5. Real Time PCR

9. Nucleic Acid Testing Market, by Sample Type

• 9.1. Blood
• 9.2. Saliva
• 9.3. Swabs
• 9.4. Tissue
• 9.5. Urine

10. Nucleic Acid Testing Market, by Target Molecule

• 10.1. DNA
• 10.2. RNA
• 10.3. Combined DNA/RNA

11. Nucleic Acid Testing Market, by Degree Of Automation

• 11.1. Manual
• 11.2. Semi-Automated
• 11.3. Fully Automated

12. Nucleic Acid Testing Market, by Clinical Purpose

• 12.1. Screening
• 12.2. Confirmatory Testing
• 12.3. Monitoring
• 12.4. Treatment Selection

13. Nucleic Acid Testing Market, by Application

• 13.1. Clinical Diagnostics
• 13.2. Drug Discovery
• 13.3. Forensics
• 13.4. Research
• 13.5. Veterinary Diagnostics

14. Nucleic Acid Testing Market, by End User

• 14.1. Academic Research Institutes
• 14.2. Diagnostic Laboratories
• 14.3. Hospitals & Clinics
• 14.4. Pharmaceutical & Biotechnology Companies

15. Nucleic Acid Testing Market, by Region

• 15.1. Asia-Pacific
• 15.2. North America
• 15.3. Latin America
• 15.4. Europe
• 15.5. Middle East
• 15.6. Africa

16. Nucleic Acid Testing Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Nucleic Acid Testing Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025

19. Company Profiles

• 19.1. Abbott Laboratories
• 19.2. Agilent Technologies, Inc.
• 19.3. Becton, Dickinson and Company
• 19.4. BGI Genomics Co., Ltd.
• 19.5. Bio-Rad Laboratories, Inc.
• 19.6. bioMerieux SA
• 19.7. Danaher Corporation
• 19.8. DiaSorin S.p.A.
• 19.9. Exact Sciences Corporation
• 19.10. F. Hoffmann-La Roche Ltd
• 19.11. Grifols, S.A.
• 19.12. Hologic, Inc.
• 19.13. Illumina, Inc.
• 19.14. Meridian Bioscience, Inc.
• 19.15. Molbio Diagnostics Private Limited
• 19.16. Mylab Discovery Solutions Pvt. Ltd.
• 19.17. Natera, Inc.
• 19.18. Oxford Nanopore Technologies plc
• 19.19. Pacific Biosciences of California, Inc.
• 19.20. Promega Corporation
• 19.21. QIAGEN N.V.
• 19.22. Quest Diagnostics Incorporated
• 19.23. QuidelOrtho Corporation
• 19.24. Revvity, Inc.
• 19.25. Sansure Biotech Inc.
• 19.26. Seegene Inc.
• 19.27. Siemens Healthineers AG
• 19.28. Sonic Healthcare Limited
• 19.29. Sysmex Corporation
• 19.30. Thermo Fisher Scientific Inc.